Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
- Conditions
- Renal InsufficiencyDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00770081
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
🇺🇸Renal Endocrine Associates, P. C., Pittsburgh, Pennsylvania, United States
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Essential Hypertension ( Mild to Moderate)
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
- Conditions
- Diabetes Mellitus, Type 2Renal Insufficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 349
- Registration Number
- NCT00765830
- Locations
- 🇪🇸
Hospital de la Ribera, Alzira, Spain
🇪🇸Hospital San Pedro de Alcantara, Caceres, Spain
🇪🇸Clinica Mediterranea de Neurociencias, Alicante, Spain
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: alb-interferon alfa 2bDrug: peg-interferon
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 525
- Registration Number
- NCT00759200
- Locations
- 🇹🇭
Novartis Investigative site, Chaingmai, Thailand
🇬🇧Novartis Investigative Site, Glasgow, United Kingdom
Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: Placebo to F12DDrug: Placebo to F12M/MFF
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00746330
- Locations
- 🇵🇪
Novartis Investigative Site, Lima, Peru
Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
- Conditions
- Smokers
- Interventions
- Biological: PlaceboBiological: NIC002
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00736047
- Locations
- 🇩🇪
Novartis Investigator Site, Neuss, Germany
🇩🇪Novartis Investigative Site, Mainz, Germany
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
- Conditions
- Alzheimer Disease
- Interventions
- Biological: CAD106Biological: Placebo
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00733863
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
🇸🇪Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
🇬🇧Moorgreen Hospital, Southampton, United Kingdom
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00732771
- Locations
- 🇫🇷
Novartis Investigator Site, France, France